TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28316280

Group type: EXPERIMENTAL
Intervention: PLAB part 1 scores
Number of subjects: 27330

Group type: EXPERIMENTAL
Intervention: PLAB part 2 scores
Number of subjects: 27330

Group type: EXPERIMENTAL
Intervention: IELTS reading scores
Number of subjects: 27330

Group type: EXPERIMENTAL
Intervention: IELTS listening scores
Number of subjects: 27330

Group type: EXPERIMENTAL
Intervention: IELTS speaking scores
Number of subjects: 27330

Group type: EXPERIMENTAL
Intervention: Multiple resits at either part of the PLAB
Number of subjects: 27330
Study: 26188167

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cannabis users
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Heavy long-term users (HLT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Light short-term users (LST)
Number of subjects: 44
Study: 23365149

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 5 mg once yearly
Number of subjects: 793

Group type: COMPARATOR
Intervention: Oral risedronate (RIS)
Number of subjects: 793
Study: 21078841

Group type: EXPERIMENTAL
Intervention: 5 mg synthetic oral THC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 mg synthetic oral THC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-dose Sativex (5.4 mg THC and 5.0 mg CBD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-dose Sativex (16.2 mg THC and 15.0 mg CBD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 mg oral THC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 mg oral THC
Number of subjects: 9
Study: 19608695

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of rotigotine (1.2 mg over 12 hours)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transdermal application of rotigotine (4.5 mg via 10-cm² patch for 24 hours)
Number of subjects: 6
Study: 16721463

Group type: EXPERIMENTAL
Intervention: One‐Step (Bisco)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gluma One Bond (Heraeus Kulzer)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Solobond M (Voco)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TenureQuik w/F (Den‐Mat)
Number of subjects: 50

Group type: COMPARATOR
Intervention: OptiBond Solo Plus (Kerr)
Number of subjects: 50
Study: 14677616

Group type: EXPERIMENTAL
Intervention: One Step adhesive with A2 Heliomolar RO liner
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT adhesive with A2 Heliomolar Flow liner
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT adhesive with A2 Bisfil 2B liner
Number of subjects: 80

Group type: COMPARATOR
Intervention: No liner used (D and H subgroups)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prime & Bond NT adhesive
Number of subjects: 80
Study: 11099054

Group type: EXPERIMENTAL
Intervention: Eradication therapy (metronidazole, amoxicillin, and omeprazole for 2 weeks) followed by placebo for 1 year
Number of subjects: 276

Group type: COMPARATOR
Intervention: Long-term omeprazole treatment (20 mg twice daily until healing, followed by 20 mg/day for 1 year)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Eradication therapy
Number of subjects: 276

Group type: COMPARATOR
Intervention: Long-term omeprazole
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Eradication therapy and long-term omeprazole
Number of subjects: 276
Study: 9350488

Group type: EXPERIMENTAL
Intervention: Speech therapy and videonasopharyngoscopy as an instrument for visual biofeedback of the velopharyngeal sphincter
Number of subjects: 17

Group type: COMPARATOR
Intervention: Speech therapy only
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All patients (including both groups)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Visual biofeedback postoperatively
Number of subjects: 17
Study: 8456422

Group type: EXPERIMENTAL
Intervention: factor VIII‐P, an intermediate purity pasteurized concentrate
Number of subjects: 218

Group type: COMPARATOR
Intervention: factor VIII‐SD, a high purity concentrate treated with solvent‐detergent
Number of subjects: 218
Study: 3529362

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg, given twice daily for 2 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo, given twice daily for 2 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 20
Study: 30563582

Group type: EXPERIMENTAL
Intervention: Quetiapine maintenance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term continuous antipsychotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-users of antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinued treatment
Number of subjects: 0
Study: 28662260

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 52

Group type: COMPARATOR
Intervention: No meditation (Control)
Number of subjects: 52
Study: 26044556

Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 428
Study: 23541105

Group type: EXPERIMENTAL
Intervention: COSMED FitMate™ metabolic system
Number of subjects: 30

Group type: COMPARATOR
Intervention: COSMED QUARK CPET research-based system
Number of subjects: 30
Study: 22071059

Group type: EXPERIMENTAL
Intervention: 10 L of oxygen by nonrebreather mask during and for 2 hours after cesarean delivery
Number of subjects: 585

Group type: COMPARATOR
Intervention: 2 L of oxygen by nasal cannula during cesarean delivery only (standard care)
Number of subjects: 585
Study: 19575268

Group type: EXPERIMENTAL
Intervention: Discharge summaries
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Follow-up providers' information
Number of subjects: 696
Study: 17053333

Group type: EXPERIMENTAL
Intervention: Well-being therapy (WBT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 111
Study: 15485007

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 102
Study: 11257644

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ureteral stents
Number of subjects: 40
Study: 9155286

Group type: EXPERIMENTAL
Intervention: Detailed psychological preparation and support
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard informal preparation
Number of subjects: 48
Study: 7960973

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment including a new 'opponens roll' maneuver and self-stretching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-treatment appliance
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal, symptom-free subjects)
Number of subjects: 20
Study: 3068344

Group type: EXPERIMENTAL
Intervention: Urapidil (30‐90 mg twice a day)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Captopril (12.5‐50 mg twice a day)
Number of subjects: 295
Study: 29679723

Group type: EXPERIMENTAL
Intervention: Ligament reconstruction group (LR group, n=31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single hook plate group (HP group, n=31)
Number of subjects: 62
Study: 25790834

Group type: EXPERIMENTAL
Intervention: Functional stabilization training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard training (stretching and quadriceps strengthening)
Number of subjects: 31
Study: 23458227

Group type: COMPARATOR
Intervention: Fentanyl pectin nasal spray (FPNS) 100 μg under Control condition (no rhinitis)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fentanyl pectin nasal spray (FPNS) 100 μg under Rhinitis condition (symptomatic without decongestant)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS) 100 μg under Treated condition (symptomatic with oxymetazoline)
Number of subjects: 54
Study: 21593499

Group type: EXPERIMENTAL
Intervention: 140 μg folic acid/d
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 400 μg folic acid/d
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 19564636

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Supportive care (SC) alone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Erythroid responders
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Flow cytometric analysis
Number of subjects: 110
Study: 16221931

Group type: EXPERIMENTAL
Intervention: Flicker frequencies in the delta band (2-4 Hz) and upper alpha band (10-11 Hz)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Flicker frequencies in the lower alpha band (8-10 Hz)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Attention directed to peripheral flicker
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Attention directed away from flicker to foveal stimuli
Number of subjects: 15
Study: 15530271

Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: 25-gauge Whitacre needle
Number of subjects: 100
Study: 11125533

Group type: EXPERIMENTAL
Intervention: Auditory model presented at 100% frequency
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Auditory model presented at 50% frequency
Number of subjects: 45

Group type: COMPARATOR
Intervention: No auditory model (0% frequency)
Number of subjects: 45
Study: 9262932

Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Norplant-II
Number of subjects: 1052
Study: 7506020

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% alone (n = 14)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with dextran 70 (n = 16)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline control (n = 16)
Number of subjects: 46
Study: 3674849

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 187

Group type: COMPARATOR
Intervention: Aminoglycoside serum levels, total aminoglycoside dose, duration of therapy, sex, peak temperature, presence of bacteremia, shock, liver cirrhosis, dehydration, previous otic pathology or renal failure, and development of renal toxicity
Number of subjects: 187
Study: 28841229

Group type: EXPERIMENTAL
Intervention: Vitamin D (300,000 IU orally 12 hours before PCI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no vitamin D)
Number of subjects: 99
Study: 26983946

Group type: EXPERIMENTAL
Intervention: CPAP therapy for 6 months
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard care for 6 months
Number of subjects: 303
Study: 24211508

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 540

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 540
Study: 23739521

Group type: EXPERIMENTAL
Intervention: Wiping of the face, mouth, and nose with a towel (wipe group)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Oronasopharyngeal suction with a bulb syringe (suction group)
Number of subjects: 488
Study: 20022872

Group type: EXPERIMENTAL
Intervention: Bone marrow stem cells (BMSCs) administered into infarct-related artery (IRA) at 4-6 days after primary PCI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bone marrow stem cells (BMSCs)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 19128603

Group type: EXPERIMENTAL
Intervention: Nasal irrigation for 3 months
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonirrigation
Number of subjects: 77
Study: 21876511

Group type: EXPERIMENTAL
Intervention: Provinols™ (4 mg/kg of body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 16199636

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (normal saline 0.9%)
Number of subjects: 110
Study: 11811575

Group type: EXPERIMENTAL
Intervention: Eccentric contractions at 25% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eccentric contractions at 50% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eccentric contractions at 75% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isometric contractions at increasing intensities
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Concentric contractions at increasing intensities
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eccentric contractions at 100% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All contraction modes at increasing intensities
Number of subjects: 10
Study: 9812110

Group type: EXPERIMENTAL
Intervention: Informed consent procedure with structured and rigorous explanation
Number of subjects: 49
Study: 7720893

Group type: EXPERIMENTAL
Intervention: jet-cutter
Number of subjects: 116

Group type: COMPARATOR
Intervention: blunt dissection
Number of subjects: 116

Group type: COMPARATOR
Intervention: CUSA
Number of subjects: 116
Study: 2503147

Group type: EXPERIMENTAL
Intervention: Weight for age
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Change in weight
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Growth monitoring
Number of subjects: 1011
Study: 774004

Group type: EXPERIMENTAL
Intervention: Coffee with various amounts of caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Uncaffeinated liquid (placebo)
Number of subjects: 12
Study: 11800181

Group type: EXPERIMENTAL
Intervention: Self-control training procedure with reinforcer immediacy competing with another influential dimension (e.g., RvI or QvI)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Self-control training procedure
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Assessment of reinforcer dimensions (R, Q, I, E)
Number of subjects: 3
Study: 31540607

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 789

Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 789
Study: 28946761

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study: 27875540

Group type: EXPERIMENTAL
Intervention: non-symbolic training
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: symbolic training
Number of subjects: 56

Group type: COMPARATOR
Intervention: control training
Number of subjects: 56
Study: 25416514

Group type: EXPERIMENTAL
Intervention: Movement Coaching (small-group face-to-face contact during inpatient rehabilitation, telephone aftercare, internet-based aftercare)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control intervention (not specified in detail)
Number of subjects: 412
Study: 23043578

Group type: EXPERIMENTAL
Intervention: Postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose temozolomide (75-100 mg/m²) followed by six cycles of adjuvant high-dose temozolomide (150-200 mg/m²)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose temozolomide
Number of subjects: 68
Study: 21921460

Group type: EXPERIMENTAL
Intervention: cilostazol (200 mg/day)
Number of subjects: 2672

Group type: COMPARATOR
Intervention: aspirin (81 mg/day)
Number of subjects: 2672
Study: 17196908

Group type: EXPERIMENTAL
Intervention: Only ATC opioid
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: ATC+PRN opioid
Number of subjects: 174

Group type: COMPARATOR
Intervention: Only PRN opioid
Number of subjects: 174

Group type: COMPARATOR
Intervention: No opioid
Number of subjects: 174
Study: 15663612

Group type: EXPERIMENTAL
Intervention: iVPA 800 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: iLAS 1000 mg
Number of subjects: 40
Study: 12603080

Group type: EXPERIMENTAL
Intervention: Glutamine load (20 g in 100 mL tap water)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (100 mL tap water)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glutamine load
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10585037

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) and blood donation (group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Iron supplementation alone (group 2)
Number of subjects: 32
Study: 8729587

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day and bezafibrate 400 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fluvastatin and cholestyramine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fluvastatin as monotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fluvastatin and bezafibrate
Number of subjects: 38
Study: 1816189

Group type: EXPERIMENTAL
Intervention: Ceftazidime 1 g
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ceftazidime 3 g
Number of subjects: 5
Study: 7049710

Group type: EXPERIMENTAL
Intervention: labetalol 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: chlorthalidone 10 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: labetalol 100 mg and chlorthalidone 10 mg combined
Number of subjects: 32
Study: 31668592

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg orally once daily for 12 weeks
Number of subjects: 977

Group type: COMPARATOR
Intervention: Placebo orally once daily for 12 weeks
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 977

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 977
Study: 28814161

Group type: EXPERIMENTAL
Intervention: Second-line ART
Number of subjects: 79

Group type: COMPARATOR
Intervention: First-line ART
Number of subjects: 79
Study: 26094849

Group type: EXPERIMENTAL
Intervention: Relaxation along a fictitious field (RAFF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: T2 mapping
Number of subjects: 50
Study: 24859111

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fecal Immunochemical Testing (FIT)
Number of subjects: 0
Study: 22166255

Group type: EXPERIMENTAL
Intervention: Aggressive tight control therapy including adalimumab (n=42), with a protocol aimed for remission (DAS < 1.6).
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional care (n=40) with traditional DMARDs (no prednisone or biologics).
Number of subjects: 82
Study: 20507035

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17656182

Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Disposable applicators
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Diaphragm
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 405
Study: 16306499

Group type: EXPERIMENTAL
Intervention: Therapeutic dose of salbutamol and fluticasone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 9
Study: 11887180

Group type: EXPERIMENTAL
Intervention: CETP gene mutation analysis using RT-PCR
Number of subjects: 225

Group type: COMPARATOR
Intervention: D442G allelic frequency analysis
Number of subjects: 225
Study: 12382595

Group type: EXPERIMENTAL
Intervention: Naturalistic PM task of logging the time at four set times for one week with varying complexity of the time schedule
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Retrospective memory tasks and event-based and time-based laboratory PM tasks
Number of subjects: 380
Study: 7890078

Group type: EXPERIMENTAL
Intervention: Pentoxifylline-treated semen
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control semen
Number of subjects: 97
Study: 2784172

Group type: EXPERIMENTAL
Intervention: Combined operations (IIA; n = 71)
Number of subjects: 275

Group type: COMPARATOR
Intervention: CAB followed by delayed CE (IIB; n = 58)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Delayed CE performed within 2 weeks after CAB
Number of subjects: 275

Group type: COMPARATOR
Intervention: Delayed CE with longer staging intervals
Number of subjects: 275

Group type: COMPARATOR
Intervention: Preliminary or simultaneous CE
Number of subjects: 275

Group type: COMPARATOR
Intervention: Delayed CE only
Number of subjects: 275

Group type: COMPARATOR
Intervention: Group I (stable cardiac disease)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Group II (unstable disease)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Group III (symptomatic or bilateral carotid stenosis)
Number of subjects: 275
Study: 305728

Group type: EXPERIMENTAL
Intervention: 0.1% dipivalyl epinephrine (DPE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.025% dipivalyl epinephrine (DPE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% dipivalyl epinephrine (DPE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% epinephrine hydrochloride
Number of subjects: 0
Study: 30782070

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 150

Group type: COMPARATOR
Intervention: Structured telephone support
Number of subjects: 150
Study: 30585337

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1200 mg plus 400 mg vitamin E
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (starch) plus 400 mg vitamin E
Number of subjects: 50
Study: 28248869

Group type: EXPERIMENTAL
Intervention: Group A (100% fatty acid component with 12.5% CMO)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Group B (80% fatty acid component with 12.5% CMO)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Group C (62.4% fatty acid component with 12.5% CMO)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Group D (starch 100%)
Number of subjects: 28
Study: 25955349

Group type: EXPERIMENTAL
Intervention: CHX‐MW (0.2% CHX mouthwash)
Number of subjects: 201

Group type: COMPARATOR
Intervention: CONTROL (no prophylaxis)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: CHX‐MW/SUB_IR (0.2% CHX mouthwash and 1% CHX subgingival irrigation)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: CHX‐MW/SUPRA_IR (0.2% CHX mouthwash and 1% CHX supragingival irrigation)
Number of subjects: 201
Study: 23837415

Group type: EXPERIMENTAL
Intervention: Patient Centered Disease Management (PCDM) intervention including collaborative care management by VA clinicians, home telemonitoring, guided patient self-management support, and screening and treatment for comorbid depression.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCDM intervention
Number of subjects: 0